Takis

Takis is a private, Rome-based biotech firm operating as both a service provider (CRO) and a therapeutic developer. Its core focus is on discovering and developing novel immunotherapies, primarily therapeutic antibodies and DNA/mRNA vaccines for oncology and infectious diseases. The company possesses over a decade of experience in drug discovery, validated preclinical models, and advanced manufacturing capabilities, positioning it as a specialized partner in the European biotech ecosystem. While it advances its own pipeline candidates towards early-phase trials, its service arm generates revenue through collaborations with pharmaceutical and research clients.

Integrated platform for immunotherapy development, including X-eVax technology for DNA/mRNA vaccine design, monoclonal antibody discovery and development, recombinant protein production, and a suite of validated preclinical models. Supported by BSL-3 and GMP manufacturing facilities.

As a CRO, Takis competes with large global players (Charles River, Labcorp) and niche preclinical boutiques. As a drug developer, it competes in the crowded but vast oncology immunotherapy space, where success depends on novel target differentiation. Its integrated Italian facilities offer a regional advantage.